eShowcase: ClinPhone Compact
Service Configures Ready-Made Solution for Randomization and Trial Supply Management
Service Configures Ready-Made Solution for Randomization and Trial Supply Management
ClinPhone (Nottingham, UK) announces its ClinPhone Compact, a new service created to meet the needs of many conventional study designs by offering a ready-made application for Interactive Voice Response and Interactive Web Response deployment.
eShowcase: ClinPhone Compact
The new service is hosted by ClinPhone and utilizes its existing infrastructure offerings of 24/7 global support, unlimited language capabilities, and an extensive toll-free network of 82 countries.
ClinPhone Compact allows pharmaceutical and biotechnology sponsors to perform central randomization, emergency code break, medication dispensation, and site and depot supplies management combined with real-time study progress reporting. Because the solution is ready-made, it minimizes the need for study-specific customization, including programming, testing, and validation. As such, this can lower sponsors' costs and accelerate timelines.
ClinPhone plc, +44 (0)115 9557555, www.clinphone.com
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
May 22nd 2025One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months achieved superior improvements on the Diabetic Retinopathy Severity Scale.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
